NYSE:CNC - Centene Stock Price, Price Target & More

$111.37 -0.85 (-0.76 %)

(As of 04/19/2018 04:00 PM ET)

Previous Close$111.37

Today's Range$111.04 - $112.43

52-Week Range$70.58 - $113.88

Volume1.03 million shs

Average Volume1.39 million shs

Market Capitalization$19.65 billion

P/E Ratio22.14

Dividend YieldN/A

Beta0.75

About Centene (NYSE:CNC)

Centene Corporation operates as a diversified and multi-national healthcare enterprise that provides programs and services to under-insured and uninsured individuals in the United States. It operates through two segments, Managed Care and Specialty Services. The Managed Care segment offers health plan coverage to individuals through government subsidized programs, including Medicaid, the State children's health insurance program, long-term care, foster care, and dual eligible individual, as well as aged, blind, or disabled programs. Its health plans include primary and specialty physician care, inpatient and outpatient hospital care, emergency and urgent care, prenatal care, laboratory and X-ray services, home-based primary care, transportation assistance, vision care, dental care, immunizations, prescriptions and limited over-the-counter drugs, specialty pharmacy, therapies, social work services, and care coordination. The Specialty Services segment provides pharmacy benefits management services; health, triage, wellness, and disease management services; vision and dental services; correctional healthcare services; home based primary care services; and integrated long-term care services, as well as care management software that automate the clinical, administrative, and technical components of care management programs. This segment offers its services and products to state programs, correctional facilities, healthcare organizations, employer groups, military service members and their families, and other commercial organizations. The company provides its services through primary and specialty care physicians, hospitals, and ancillary providers. Centene Corporation was founded in 1984 and is headquartered in St. Louis, Missouri.

Receive CNC News and Ratings via Email

Sign-up to receive the latest news and ratings for CNC and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Hospital & medical service plans

Sub-IndustryManaged Health Care

SectorMedical

SymbolNYSE:CNC

CUSIP15135B10

Webwww.centene.com

Phone314-725-4477

Debt

Debt-to-Equity Ratio0.68%

Current Ratio0.93%

Quick Ratio0.93%

Price-To-Earnings

Trailing P/E Ratio22.14

Forward P/E Ratio15.47

P/E Growth1.07

Sales & Book Value

Annual Sales$48.38 billion

Price / Sales0.40

Cash Flow$7.1944 per share

Price / Cash15.48

Book Value$39.78 per share

Price / Book2.80

Profitability

EPS (Most Recent Fiscal Year)$5.03

Net Income$828 million

Net Margins1.71%

Return on Equity13.68%

Return on Assets4.08%

Miscellaneous

Employees33,700

Outstanding Shares175,270,000

How to Become a New Pot Stock Millionaire

Centene (NYSE:CNC) Frequently Asked Questions

What is Centene's stock symbol?

Centene trades on the New York Stock Exchange (NYSE) under the ticker symbol "CNC."

How were Centene's earnings last quarter?

Centene Co. (NYSE:CNC) issued its quarterly earnings results on Tuesday, February, 6th. The company reported $0.97 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.94 by $0.03. The company earned $12.81 billion during the quarter, compared to the consensus estimate of $12.25 billion. Centene had a return on equity of 13.68% and a net margin of 1.71%. Centene's revenue was up 7.5% on a year-over-year basis. During the same period last year, the company earned $1.19 earnings per share. View Centene's Earnings History.

When is Centene's next earnings date?

Centene is scheduled to release their next quarterly earnings announcement on Tuesday, April, 24th 2018. View Earnings Estimates for Centene.

What guidance has Centene issued on next quarter's earnings?

Centene updated its FY18 earnings guidance on Tuesday, February, 6th. The company provided earnings per share guidance of $6.95-7.35 for the period, compared to the Thomson Reuters consensus EPS estimate of $5.76. The company issued revenue guidance of $60.6-61.4 billion, compared to the consensus revenue estimate of $60.19 billion.

What price target have analysts set for CNC?

18 brokers have issued twelve-month price targets for Centene's shares. Their predictions range from $75.00 to $135.00. On average, they anticipate Centene's stock price to reach $109.8824 in the next twelve months. View Analyst Ratings for Centene.

What are Wall Street analysts saying about Centene stock?

Here are some recent quotes from research analysts about Centene stock:

1. According to Zacks Investment Research, "In a year's time, Centene's shares have outperformed the industry. The company’s strong and consistent performance is likely to have generated confidence among investors. It has seen substantial inorganic growth in the last five years. The acquisition of Health Net in 2016 bolstered the company’s growth, expansion as well as its asset base. Its solid financial position also provides a major boost to its capital deployment initiatives. The company’s strong Managed care segment also contributes to its strong results. The guidance raise for 2018 instills shareholders' confidence in the company. Centene has seen the Zacks Consensus Estimate for 2018 earnings being revised upward in the last 60 days. However, rising debt burden hurts the company's profitability. Moreover, increasing expenses also continue to weigh on the margins. The company will release first quarter 2018 results on Apr 24." (4/10/2018)
2. Cantor Fitzgerald analysts commented, "This morning, Centene filed an 8-K which indicates that it will contribute $340 million (over five years) to New York State in conjunction with the Fidelis acquisition." (4/2/2018)

Who are some of Centene's key competitors?

Some companies that are related to Centene include Takeda Pharmaceutical (TKPYY), Illumina (ILMN), Baxter International (BAX), Regeneron (REGN), Hospital Co. of America (HCA), Fresenius Medical Care (FMS), Astellas Pharma (ALPMY), McKesson (MCK), Essilor International (ESLOY), Actelion (ALIOF), Edwards Lifesciences (EW), Shire (SHP), Alexion Pharmaceuticals (ALXN), Zimmer Biomet (ZBH), Align Technology (ALGN), Sunny Optical Technology (Group) (SNPTF), Mylan (MYL) and AmerisourceBergen (ABC).

Who are Centene's key executives?

Centene's management team includes the folowing people:

Mr. Michael Frederic Neidorff, Chairman & CEO (Age 75)
Ms. Cynthia J. Brinkley, Pres & COO (Age 58)
Mr. Jeffrey Alan Schwaneke CPA, Exec., CFO & Treasurer (Age 42)
Mr. Keith Harvey Williamson, Exec. VP, Gen. Counsel & Corp. Sec. (Age 66)
Mr. Jesse N. Hunter, Exec. VP & Chief Strategy Officer (Age 42)

Has Centene been receiving favorable news coverage?

Media coverage about CNC stock has been trending somewhat positive recently, according to Accern Sentiment Analysis. Accern identifies positive and negative press coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Centene earned a media sentiment score of 0.13 on Accern's scale. They also assigned headlines about the company an impact score of 46.72 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the near term.

How do I buy shares of Centene?

Shares of CNC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Centene's stock price today?

One share of CNC stock can currently be purchased for approximately $111.37.

How big of a company is Centene?

Centene has a market capitalization of $19.65 billion and generates $48.38 billion in revenue each year. The company earns $828 million in net income (profit) each year or $5.03 on an earnings per share basis. Centene employs 33,700 workers across the globe.

How can I contact Centene?

Centene's mailing address is 7700 FORSYTH BOULEVARD, ST LOUIS MO, 63105. The company can be reached via phone at 314-725-4477 or via email at [email protected]

MarketBeat Community Rating for Centene (CNC)

Community Ranking:		3.1 out of 5 ( )
Outperform Votes:		706 (Vote Outperform)
Underperform Votes:		448 (Vote Underperform)
Total Votes:		1,154

MarketBeat's community ratings are surveys of what our community members think about Centene and other stocks. Vote "Outperform" if you believe CNC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CNC will underperform the S&P 500 over the long term. You may vote once every thirty days.

Centene (NYSE:CNC) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

18 Wall Street analysts have issued ratings and price targets for Centene in the last 12 months. Their average twelve-month price target is $109.8824, suggesting that the stock has a possible downside of 1.34%. The high price target for CNC is $135.00 and the low price target for CNC is $75.00. There are currently 3 hold ratings and 15 buy ratings for the stock, resulting in a consensus rating of "Buy."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Buy	Buy	Buy	Buy
Consensus Rating Score:	2.83	2.83	2.74	2.68
Ratings Breakdown:	0 Sell Rating(s) 3 Hold Rating(s) 15 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 3 Hold Rating(s) 15 Buy Rating(s) 0 Strong Buy Rating(s)	1 Sell Rating(s) 3 Hold Rating(s) 15 Buy Rating(s) 0 Strong Buy Rating(s)	1 Sell Rating(s) 4 Hold Rating(s) 14 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$109.8824	$109.8824	$103.50	$94.9444
Price Target Upside:	1.34% downside	6.59% upside	0.89% upside	4.43% upside

Centene (NYSE:CNC) Consensus Price Target History

Price Target History for Centene (NYSE:CNC)

Centene (NYSE:CNC) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
4/2/2018	Cantor Fitzgerald	Reiterated Rating	Buy	$125.00	Low
3/26/2018	BMO Capital Markets	Reiterated Rating	Buy		Low
2/13/2018	Leerink Swann	Reiterated Rating	Market Perform -> Market Perform	$100.00 -> $90.00	Low
2/7/2018	Credit Suisse Group	Boost Price Target	Neutral -> Neutral	$110.00 -> $112.00	Low
2/7/2018	Morgan Stanley	Boost Price Target	Overweight -> Overweight	$118.00 -> $126.00	Medium
2/7/2018	Citigroup	Reiterated Rating	Outperform	$122.00 -> $130.00	Low
1/3/2018	Goldman Sachs	Initiated Coverage	Buy	$135.00	Medium
12/20/2017	Oppenheimer	Boost Price Target	Outperform	$111.00 -> $122.00	Low
12/18/2017	Jefferies Group	Boost Price Target	Buy -> Buy	$112.00 -> $115.00	Medium
12/18/2017	Piper Jaffray	Reiterated Rating	Buy	$134.00	High
10/24/2017	Cowen	Reiterated Rating	Buy	$115.00	N/A
9/14/2017	Deutsche Bank	Reiterated Rating	Buy	$95.00 -> $111.00	Low
7/26/2017	UBS	Reiterated Rating	Buy	$88.00 -> $95.00	Low
7/14/2017	Bank of America	Boost Price Target	Buy	$93.00 -> $95.00	Low
7/11/2017	Sanford C. Bernstein	Reiterated Rating	Outperform		Medium
5/22/2017	JPMorgan Chase	Downgrade	Overweight -> Neutral	$75.00	Medium
4/26/2017	Evercore ISI	Boost Price Target	Outperform	$80.00 -> $83.00	High
4/26/2017	Stifel Nicolaus	Boost Price Target	Buy	$80.00 -> $85.00	High
2/8/2017	Barclays	Boost Price Target	Overweight	$75.00 -> $79.00	N/A
9/7/2016	Wedbush	Reiterated Rating	Outperform	$85.00	N/A
9/1/2016	FBR & Co	Reiterated Rating	Buy		N/A
6/28/2016	Wolfe Research	Initiated Coverage	Market Perform	$80.00	N/A
6/20/2016	Wells Fargo	Reiterated Rating	Buy		N/A

(Data available from 4/19/2016 forward)

Centene (NYSE:CNC) Earnings History and Estimates Chart

Earnings by Quarter for Centene (NYSE:CNC)

Centene (NYSE:CNC) Earnings Estimates

2018 EPS Consensus Estimate: $7.16
2019 EPS Consensus Estimate: $8.21

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	3	$1.90	$2.00	$1.95
Q2 2018	3	$1.80	$1.92	$1.88
Q3 2018	3	$1.90	$1.95	$1.92
Q4 2018	3	$1.38	$1.46	$1.41
Q1 2019	1	$2.28	$2.28	$2.28
Q2 2019	1	$2.18	$2.18	$2.18
Q3 2019	1	$2.14	$2.14	$2.14
Q4 2019	1	$1.61	$1.61	$1.61

Centene (NYSE CNC) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
4/24/2018		$1.61					N/A
2/6/2018	Q4 2017	$0.94	$0.97	$12.2478 billion	$12.8060 billion	View	Listen
10/24/2017	Q3 2017	$1.24	$1.35	$11.7479 billion	$11.8980 billion	View	N/A
7/25/2017	Q2 2017	$1.30	$1.59	$11.6936 billion	$11.9540 billion	View	N/A
4/25/2017	Q1 17	$1.06	$1.12	$11.4381 billion	$11.7240 billion	View	N/A
2/7/2017	Q416	$1.11	$1.19	$10.94 billion	$11.91 billion	View	N/A
10/25/2016	Q316	$1.15	$1.11	$10.96 million	$10.85 billion	View	Listen
7/26/2016	Q216	$1.09	$1.29	$10.80 billion	$10.90 billion	View	Listen
4/26/2016	Q116	$0.74	$0.74	$7.88 billion	$6.95 billion	View	Listen
2/9/2016	Q415	$0.82	$0.95	$6.14 billion	$6.30 billion	View	N/A
10/27/2015	Q315	$0.78	$0.84	$5.79 billion	$5.82 billion	View	Listen
7/28/2015	Q215	$0.69	$0.73	$5.54 billion	$5.51 billion	View	Listen
4/28/2015	Q115	$0.48	$0.52	$5.12 billion	$5.13 billion	View	Listen
2/3/2015	Q414	$1.70	$1.74	$4.62 billion	$4.42 billion	View	Listen
10/28/2014	Q314	$0.96	$1.22	$4.23 billion	$4.35 billion	View	Listen
7/22/2014	Q214	$0.73	$0.79	$3.66 billion	$4.02 billion	View	Listen
4/22/2014	Q1	$0.44	$0.57	$3.25 billion	$3.35 billion	View	Listen
2/4/2014	Q413	$0.83	$0.84	$2.93 billion	$2.86 billion	View	Listen
10/22/2013	Q313	$0.84	$0.87	$2.68 billion	$2.70 billion	View	Listen
7/23/2013	Q2 2013	$0.62	$0.77	$2.63 billion	$2.73 billion	View	Listen
4/23/2013	Q1 2013	$0.38	$0.42	$2.46 billion	$2.54 billion	View	Listen
2/5/2013	Q4 2012	$0.32	$0.17	$2.40 billion	$2.30 billion	View	Listen
10/23/2012		$0.48	$0.07			View	N/A
7/24/2012		($0.10)	($0.16)			View	N/A
4/24/2012		$0.48	$0.45			View	N/A
2/7/2012		$0.55	$0.57			View	N/A
10/25/2011		$0.53	$0.55			View	N/A
7/26/2011		$0.54	$0.54			View	N/A
4/26/2011		$0.42	$0.46			View	N/A
2/8/2011		$0.48	$0.50			View	N/A
10/26/2010	Q3 2010	$0.24	$0.24			View	N/A
7/27/2010	Q2 2010	$0.21	$0.23			View	N/A
4/27/2010	Q1 2010	$0.19	$0.21			View	N/A
2/9/2010	Q4 2009	$0.26	$0.27			View	N/A
10/27/2009	Q3 2009	$0.25	$0.26			View	N/A
7/28/2009	Q2 2009	$0.23	$0.23			View	N/A
4/28/2009	Q1 2009	$0.20	$0.21			View	N/A
2/10/2009	Q4 2008	$0.26	$0.26			View	N/A
10/28/2008	Q3 2008	$0.23	$0.24			View	N/A
7/22/2008	Q2 2008	$0.19	$0.20			View	N/A
4/22/2008	Q1 2008	$0.27	$0.29			View	N/A
2/8/2008	Q4 2007	$0.24	$0.10			View	N/A

(Earnings results data provided by Zacks Investment Research)

Centene (NYSE:CNC) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date

(Data available from 1/1/2013 forward)

Centene (NYSE CNC) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 3.00%
Institutional Ownership Percentage: 90.58%

Insider Trading History for Centene (NYSE:CNC)

Institutional Ownership by Quarter for Centene (NYSE:CNC)

Centene (NYSE CNC) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/12/2018	Christopher D. Bowers	EVP	Sell	4,800	$102.27	$490,896.00
2/13/2018	Stephen Wallace	Director	Buy	5,000	$0.08	$400.00
2/8/2018	Robert K. Ditmore	Director	Sell	8,750	$104.13	$911,137.50
1/30/2018	Stephen Wallace	Director	Buy	5,000	$0.09	$450.00
1/8/2018	Robert K. Ditmore	Director	Sell	8,750	$104.30	$912,625.00
1/2/2018	Keith H. Williamson	EVP	Sell	5,000	$100.11	$500,550.00
12/19/2017	Jesse N. Hunter	EVP	Sell	10,000	$98.73	$987,300.00
10/26/2017	Robert K. Ditmore	Director	Sell	4,167	$90.42	$376,780.14
8/1/2017	Christopher D. Bowers	EVP	Sell	4,000	$79.43	$317,720.00
7/27/2017	Robert K. Ditmore	Director	Sell	4,167	$82.59	$344,152.53
7/6/2017	Michael F. Neidorff	Chairman	Sell	35,000	$80.26	$2,809,100.00
6/12/2017	Richard A. Gephardt	Director	Sell	4,350	$77.38	$336,603.00
6/2/2017	Mark J. Brooks	SVP	Sell	2,161	$75.43	$163,004.23
6/2/2017	Robert K. Ditmore	Director	Sell	3,900	$75.43	$294,177.00
5/1/2017	Jesse N. Hunter	EVP	Sell	5,000	$74.40	$372,000.00
5/1/2017	Stephen Wallace	Director	Buy	100,000	$0.04	$4,000.00
4/27/2017	Christopher D. Bowers	EVP	Sell	3,150	$72.80	$229,320.00
4/27/2017	Robert K. Ditmore	Director	Sell	4,167	$72.43	$301,815.81
3/27/2017	Keith H. Williamson	EVP	Sell	6,000	$70.03	$420,180.00
3/13/2017	Jeffrey A. Schwaneke	CFO	Sell	2,000	$68.52	$137,040.00
2/13/2017	Jesse N. Hunter	EVP	Sell	5,000	$69.54	$347,700.00
12/1/2016	Mark J. Brooks	SVP	Sell	1,099	$58.00	$63,742.00
11/7/2016	Jesse N. Hunter	EVP	Sell	5,000	$65.00	$325,000.00
10/3/2016	Carol Goldman	VP	Sell	10,000	$66.36	$663,600.00
10/3/2016	Kenneth Rone Baldwin	EVP	Sell	6,000	$66.58	$399,480.00
9/7/2016	Robert K. Ditmore	Director	Buy	150	$67.00	$10,050.00
7/1/2016	Kenneth Rone Baldwin	EVP	Sell	6,000	$71.00	$426,000.00
6/29/2016	Richard A. Gephardt	Director	Sell	15,910	$68.89	$1,096,039.90
6/24/2016	Keith H. Williamson	EVP	Sell	4,000	$70.00	$280,000.00
6/6/2016	Mark J Brooks	SVP	Sell	3,914	$65.01	$254,449.14	30,605
4/28/2016	Jesse N Hunter	EVP	Sell	10,000	$65.17	$651,700.00	216,329
4/1/2016	Kenneth Rone Baldwin	EVP	Sell	6,000	$60.87	$365,220.00	123,494
3/23/2016	Carol Goldman	VP	Sell	15,000	$62.96	$944,400.00	78,500
1/4/2016	Kenneth Rone Baldwin	EVP	Sell	6,000	$64.68	$388,080.00	131,770
12/22/2015	Carol Goldman	VP	Sell	25,000	$65.19	$1,629,750.00	97,448
12/22/2015	Jeffrey A Schwaneke	CAO	Sell	2,000	$65.09	$130,180.00	82,574
10/29/2015	Carol Goldman	VP	Sell	5,000	$60.88	$304,400.00	103,614
7/1/2015	Carol Goldman	VP	Sell	5,000	$81.20	$406,000.00
6/22/2015	Keith H Williamson	EVP	Sell	7,000	$80.87	$566,090.00
6/18/2015	William N Scheffel	CFO	Sell	25,290	$79.14	$2,001,450.60
5/4/2015	Donald G Imholz	EVP	Sell	5,000	$65.08	$325,400.00
4/30/2015	Carol Goldman	VP	Sell	15,998	$63.48	$1,015,553.04
4/30/2015	Donald G Imholz	EVP	Sell	5,000	$63.72	$318,600.00
4/30/2015	Robert K Ditmore	Director	Sell	15,000	$63.83	$957,450.00
4/6/2015	Michael F Neidorff	CEO	Sell	10,000	$70.43	$704,300.00
4/1/2015	Jesse N Hunter	EVP	Sell	5,000	$69.66	$348,300.00
3/19/2015	Keith H Williamson	EVP	Sell	5,000	$70.18	$350,900.00
3/13/2015	Tommy G Thompson	Director	Sell	16,000	$65.36	$1,045,760.00
3/9/2015	Robert K Ditmore	Director	Sell	15,000	$63.19	$947,850.00
1/2/2015	Carol Goldman	VP	Sell	8,400	$104.87	$880,908.00
1/2/2015	Jesse N Hunter	EVP	Sell	2,500	$104.87	$262,175.00
12/16/2014	Jeffrey A Schwaneke	CAO	Sell	5,000	$101.80	$509,000.00
10/1/2014	Jesse N Hunter	EVP	Sell	2,500	$81.42	$203,550.00
9/22/2014	Carol Goldman	VP	Sell	12,500	$81.85	$1,023,125.00
9/18/2014	Donald G Imholz	EVP	Sell	5,000	$80.10	$400,500.00
9/15/2014	Keith H Williamson	EVP	Sell	4,000	$77.48	$309,920.00
9/9/2014	Jeffrey A Schwaneke	CAO	Sell	1,000	$79.51	$79,510.00
9/9/2014	Jesse N Hunter	EVP	Sell	5,000	$79.35	$396,750.00
9/2/2014	Donald G Imholz	EVP	Sell	5,000	$77.32	$386,600.00
8/28/2014	Jeffrey A Schwaneke	CAO	Sell	1,000	$77.02	$77,020.00
5/12/2014	Jason Harrold	EVP	Sell	2,500	$70.00	$175,000.00	45,048
4/2/2014	Jason Harrold	EVP	Sell	5,000	$62.19	$310,950.00	48,382
3/31/2014	Edmund Kroll	SVP	Sell	5,000	$62.00	$310,000.00	41,780
3/31/2014	William Scheffel	CFO	Sell	17,895	$61.99	$1,109,311.05	85,528
2/6/2014	Jesse Hunter	EVP	Sell	5,000	$61.66	$308,300.00	97,650
2/6/2014	Michael Neidorff	CEO	Sell	10,000	$62.00	$620,000.00	1,745,926
12/17/2013	Orlando Ayala	Director	Buy	17,600	$56.41	$992,816.00	29,193
7/25/2013	Jeffrey A Schwaneke	CAO	Sell	3,000	$57.40	$172,200.00
7/25/2013	Jesse N Hunter	EVP	Sell	5,000	$57.41	$287,050.00
6/13/2013	Keith H Williamson	EVP	Sell	5,800	$50.25	$291,450.00
6/7/2013	Donald G Imholz	EVP	Sell	5,000	$50.00	$250,000.00
6/3/2013	Carol Goldman	VP	Sell	10,000	$49.28	$492,800.00
6/3/2013	Jesse N Hunter	EVP	Sell	6,000	$48.28	$289,680.00
5/30/2013	Jason M Harrold	EVP	Sell	5,000	$50.80	$254,000.00
5/30/2013	Jeffrey A Schwaneke	CAO	Sell	3,000	$50.68	$152,040.00
5/30/2013	William N Scheffel	CFO	Sell	22,191	$50.80	$1,127,302.80
5/10/2013	Keith H Williamson	EVP	Sell	3,000	$50.00	$150,000.00
12/4/2012	Carol Goldman	VP	Sell	15,000	$45.15	$677,250.00
12/4/2012	Keith H Williamson	EVP	Sell	9,000	$45.10	$405,900.00

(Data available from 1/1/2013 forward)

Centene (NYSE CNC) News Headlines

Source:

Date	Headline
	Amid a $1.2 billion building boom in Clayton is a 2-block 'opportunity' up for grabs www.bizjournals.com - April 19 at 5:13 PM
	[$$] New York Acted Fairly in the Fidelis Care Sale finance.yahoo.com - April 19 at 5:13 PM
	Sanford C. Bernstein Reaffirms "Outperform" Rating for Centene (CNC) www.americanbankingnews.com - April 19 at 3:34 PM
	FY2020 Earnings Estimate for Centene Co. (CNC) Issued By Leerink Swann www.americanbankingnews.com - April 18 at 8:57 AM
	Today’s Research Reports on Trending Tickers: CVS Health and Centene finance.yahoo.com - April 17 at 9:10 AM
	Analysts Set Expectations for Centene Co.'s FY2021 Earnings (CNC) www.americanbankingnews.com - April 17 at 7:05 AM
	Centene (CNC) Scheduled to Post Earnings on Tuesday www.americanbankingnews.com - April 17 at 3:11 AM
	Centene Co. (CNC) Expected to Announce Quarterly Sales of $13.17 Billion www.americanbankingnews.com - April 16 at 3:09 AM
	Centene (CNC) Receives "Buy" Rating from Piper Jaffray www.americanbankingnews.com - April 15 at 7:48 PM
	Centene (CNC) Upgraded to Buy by ValuEngine www.americanbankingnews.com - April 15 at 7:48 PM
	Centene (CNC) Upgraded to "Strong-Buy" at Zacks Investment Research www.americanbankingnews.com - April 15 at 5:06 PM
	Centene Co. (CNC) Expected to Announce Earnings of $1.93 Per Share www.americanbankingnews.com - April 14 at 1:22 PM
	Why Health Net is pulling out of the Arizona employer health insurance market finance.yahoo.com - April 13 at 9:15 AM
	Zacks Investment Research Lowers Centene (CNC) to Hold www.americanbankingnews.com - April 10 at 2:51 PM
	Cuomo Loots A Catholic Charity www.wsj.com - April 10 at 9:12 AM
	Centene's (CNC) Buy Rating Reaffirmed at Cantor Fitzgerald www.americanbankingnews.com - April 5 at 7:26 PM
	Centene (CNC) Stock Rating Reaffirmed by Oppenheimer www.americanbankingnews.com - April 5 at 7:26 PM
	Oppenheimer Increases Centene (CNC) Price Target to $111.00 www.americanbankingnews.com - April 5 at 2:15 PM
	Centene To Hold 2018 Annual Meeting Following First Quarter Financial Results Conference Call www.prnewswire.com - April 5 at 9:33 AM
	Cooper (COO) Buys LifeGlobal to Widen Fertility Device Line finance.yahoo.com - April 4 at 4:39 PM
	Here's Why You Should Invest in ABIOMED (ABMD) Right Now finance.yahoo.com - April 4 at 4:39 PM
	IRCCO Picks Cerner's HealtheIntent for Patients of Illinois finance.yahoo.com - April 3 at 4:55 PM
	Seagate Technology, Cadence Design Systems, NVIDIA, Micron and Centene highlighted as Zacks Bull and Bear of the Day finance.yahoo.com - April 3 at 8:52 AM
	Centene's (CNC) "Buy" Rating Reaffirmed at Cantor Fitzgerald www.americanbankingnews.com - April 2 at 11:16 AM
	Today’s Research Reports on Trending Tickers: Centene and Alexion Pharmaceuticals finance.yahoo.com - April 2 at 9:50 AM
	Centene (CNC) Upgraded at ValuEngine www.americanbankingnews.com - March 31 at 3:20 PM
	Centene Corp (CNC) Given Average Recommendation of "Buy" by Analysts www.americanbankingnews.com - March 31 at 9:54 AM
	Centene to fill ABQ leadership team with local candidates www.bizjournals.com - March 29 at 4:52 PM
	The Biggest Movers: Centene Shines; Alliance Data Drops finance.yahoo.com - March 29 at 4:52 PM
	Centene Corp (CNC) Expected to Announce Earnings of $1.93 Per Share www.americanbankingnews.com - March 28 at 3:14 PM
	Centene's (CNC) "Buy" Rating Reaffirmed at BMO Capital Markets www.americanbankingnews.com - March 27 at 9:43 AM
	See what the IHS Markit Score report has to say about Centene Corp. finance.yahoo.com - March 26 at 9:46 AM
	More Angst About Facebook: Global Week Ahead finance.yahoo.com - March 26 at 9:46 AM
	Centene (CNC) Rating Increased to Buy at ValuEngine www.americanbankingnews.com - March 25 at 7:32 PM
	Centene Hasn't Fixed Obamacare Plan Doctor Shortage, Washington State Says www.bloomberg.com - March 24 at 5:22 PM
	Centene Hasn’t Fixed Obamacare Plan Doctor Shortage, Washington State Says finance.yahoo.com - March 22 at 5:17 PM
	Centene Corporation (NYSE:CNC), Euronet Worldwide, Inc ... - Benzinga www.benzinga.com - March 21 at 9:29 AM
	5 Best Momentum Stocks to Buy Using Driehaus Strategy finance.yahoo.com - March 21 at 9:29 AM
	The 6 Most Inexpensive Growth Stocks To Buy Now investorplace.com - March 20 at 5:57 PM
	Sacramento receives proposal for possible Centene campus www.bizjournals.com - March 20 at 5:00 PM
	Should Value Investors Pick Centene Corporation (CNC) Stock? finance.yahoo.com - March 20 at 5:00 PM
	5 Reasons Why Centene is an Attractive Bet for Investors finance.yahoo.com - March 20 at 5:00 PM
	Centene Makes Investment in RxAdvance, Builds Partnership www.zacks.com - March 15 at 10:09 AM
	Centene (CNC) Makes Initial Investment in RxAdvance www.streetinsider.com - March 15 at 10:09 AM
	Ex-Apple Chief on new venture, RxAdvance finance.yahoo.com - March 15 at 10:09 AM
	Ex-Apple chief: Centene partnership with pharmacy start-up will drive better care with lower costs www.cnbc.com - March 15 at 8:34 AM
	Cigna on Raters' Radar After Express Scripts Bid, Stock Down - Nasdaq www.nasdaq.com - March 14 at 4:50 PM
	Cigna on Raters' Radar After Express Scripts Bid, Stock Down finance.yahoo.com - March 14 at 12:00 PM
	Insider Selling: Centene Corp (CNC) EVP Sells 4,800 Shares of Stock www.americanbankingnews.com - March 13 at 10:10 PM
	Analyst: Why Diplomat Could Be Amazon's Ticket Into The Pharma Space - Benzinga www.benzinga.com - March 13 at 5:16 PM

Centene (NYSE:CNC) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

Centene (NYSE:CNC) Income Statement, Balance Sheet and Cash Flow Statement

Centene (NYSE CNC) Stock Chart for Thursday, April, 19, 2018

Loading chart…

This page was last updated on 4/19/2018 by MarketBeat.com Staff